Nexsen (ASX:NXN) advances StrepSure® with FDA feedback confirming U.S. approval pathway

Nexsen (ASX:NXN) has taken a defined step toward U.S. market entry for its lead diagnostic, StrepSure®, following the completion of a Pre Submission meeting with the U.S. Food and Drug Administration under the Q Submission program.

The outcome provides formal regulatory feedback that supports the company’s proposed pathway and reduces uncertainty ahead of submission, marking a key milestone as Nexsen progresses its first product through the FDA system.

Highlights

• Pre Submission meeting completed under FDA Q Submission program
• Positive feedback on regulatory strategy, intended use and clinical validation approach
• Clearer and lower risk pathway established toward U.S. market authorisation
• First product advancing through FDA regulatory pathway
• Activities progressing toward regulatory submission and planned commercial rollout
• Early validation of broader rapid point of care diagnostics platform

The Q Submission process provides structured engagement with the FDA ahead of formal submission, allowing companies to refine regulatory strategy and align on expectations.

In Nexsen’s case, the feedback received supports its intended pathway to U.S. market authorisation for StrepSure®, while also providing increased clarity on regulatory requirements.

This reduces execution risk as the company advances toward submission, a critical consideration given this is its first product progressing through the FDA framework.

StrepSure® is positioned as a rapid lateral flow point of care diagnostic for the detection of Group B Streptococcus in pregnant women, addressing a condition that affects an estimated 18% globally.

Current testing methods rely on pathology laboratories and can take days to deliver results, limiting their utility in time critical clinical settings.

By contrast, StrepSure® is designed to deliver results in approximately 20 to 30 minutes at the point of care, enabling real time clinical decision making without the need for laboratory equipment.

The U.S. market context is defined by GBS screening being integrated into standard prenatal care across a large annual birth cohort, which provides a repeatable and scalable testing opportunity.

The milestone carries broader corporate implications beyond the lead product.

As Nexsen’s first diagnostic to move through the FDA regulatory pathway, the process serves as validation of the company’s regulatory strategy and internal capability to navigate U.S. requirements.

Nexsen’s Managing Director, Mark Muzzin, commented:

“This is a significant milestone for Nexsen and a meaningful de risking event for StrepSure®. The FDA’s feedback not only provides clarity and confidence in our regulatory pathway toward U.S. approval but also highlights the potential scale and commercial impact of StrepSure® in the maternal health market. With this alignment in place, we are advancing our regulatory and commercial execution to bring StrepSure® toward the world’s largest maternal health market and to leverage learnings for our broader diagnostic pipeline.”

In parallel with regulatory engagement, Nexsen has been advancing workstreams to support submission and commercial readiness, with further updates on regulatory and market rollout plans expected in due course.

Importantly, StrepSure® remains an investigational device and has not yet received regulatory approval for clinical use in any jurisdiction, underscoring the staged nature of the pathway ahead.

The company’s broader focus on rapid point of care diagnostics targets conditions traditionally reliant on lab based testing, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems.

Within this context, the FDA feedback represents both a product specific milestone and an early validation of Nexsen’s platform approach.

From an industry perspective, the development of diagnostics capable of delivering near real time results at the point of care aligns with ongoing shifts in healthcare delivery models, particularly in areas requiring immediate clinical decision making.

Nexsen’s next phase centres on progressing toward formal submission and advancing commercial execution, with regulatory clarity now providing a more defined pathway forward.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.